Bolder BioTechnology, Inc.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. Our products are designed to last longer in the body, which allows them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. We intend to commercialize these products independently and through strategic alliances with corporate partners.

Contact Details: 2945 Wilderness Place, Suite 100 Boulder Colorado 80301 United States of America Tel: 303-420-4420 Fax: 303-420-4426 Email: jcox@bolderbio.com WWW: www.bolderbio.com/

Loading...

Press Releases on Bolder BioTechnology, Inc.:
Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product	16th December, 2008	Bolder BioTechnology, Inc.	BOULDER, Colo., Dec. 16 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National

BioNews Results for Bolder BioTechnology, Inc.:
Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA	News-Medical.Net:  Oct 19 2009 1:38PM Matching: bolder biotechnology inc
Bolder BioTechnology Receives $1.2 Million NIH Grant to Continue Development of Long-Acting EPO Analog for Chr	Pharma Live:  Sep 17 2009 8:45PM Matching: bolder biotechnology inc
Bolder BioTechnology Receives $1.2 Million NIH Grant to Continue Development of Long-Acting EPO Analog for Chr	PR Newswire via Yahoo!:  Sep 17 2009 3:27PM Matching: bolder biotechnology inc
Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating	Pharma Live:  Sep 17 2009 8:45PM Matching: bolder biotechnology inc
Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating	PR Newswire via Yahoo!:  Sep 17 2009 3:27PM Matching: bolder biotechnology inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Bolder BioTechnology, Inc. news.

Bolder BioTechnology, Inc. Patents:
US Patent No.	Title
7560101	Method of treatment of an infection in an animal with GM-CSF cysteine muteins in the proximal region to helix A
6753165	Methods for making proteins containing free cysteine residues
7148333	Cysteine variants of granulocyte-macrophage colony-stimulating factor
7153943	Derivatives of growth hormone and related proteins, and methods of use thereof
7214779	Termini cysteine-added variants of granulocyte-macrophage colony stimulating factor
→View more Bolder BioTechnology, Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 361 times since April 2007, the link to the organisation's website has been followed 72 times

Recent Search Terms used to find this page: Bolder BioTechnology | bolder biotechnology | human resources bolder biotechnology | bolder biotech 2009 | bolder 2009 420 | .

Search for more companies in Boulder

Search for more companies in Colorado

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Bolder BioTechnology, Inc.